Detalhe da pesquisa
1.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662991
2.
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
Blood
; 139(8): 1198-1207, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34469514
3.
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax.
Blood
; 135(25): 2266-2270, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32244251
4.
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre.
Intern Med J
; 52(7): 1286-1287, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35879233
5.
Treatment approaches for patients with TP53-mutated mantle cell lymphoma.
Lancet Haematol
; 10(2): e142-e154, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725119
6.
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.
Blood Adv
; 6(20): 5589-5592, 2022 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35901282
7.
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.
Blood Adv
; 6(2): 503-508, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34861696
8.
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.
Blood Adv
; 5(20): 4054-4058, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34478505
9.
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy.
Blood Adv
; 4(19): 4849-4859, 2020 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33031542
10.
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months.
Blood Adv
; 4(1): 165-173, 2020 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31935286
11.
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbß3 in mice and humans.
Blood Adv
; 3(24): 4298-4311, 2019 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869418
12.
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Blood Adv
; 8(6): 1439-1443, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38231032
13.
Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?
Leuk Lymphoma
; 61(10): 2283-2285, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32900243
14.
Microvesicles in chronic lymphocytic leukemia: ready for prime time in the clinic?
Leuk Lymphoma
; 58(6): 1281-1282, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28271951